Companies · ABT
Abbott Laboratories
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 4, 2026
Abbott posts 14.8% organic sales growth in Q3 2026, driven by Exact Sciences acquisition and core device momentum.
Abbott's third-quarter sales of $13.0 billion grew 14.8 percent excluding foreign exchange, powered by the March 2026 completion of its $20.6 billion Exact Sciences acquisition and organic mid-to-high single-digit growth across Medical Devices and Established Pharmaceuticals. Diagnostic Products surged 46.6 percent organically following Exact Sciences' $2.0 billion contribution year-to-date, while Diabetes Care delivered 7.7 percent organic growth on continuous glucose monitoring (CGM) expansion. Gross margin compressed to 50.3 percent in Q3 from 51.7 percent a year ago, primarily due to Exact Sciences' intangible amortization and higher costs, though margin improvement initiatives and favorable business mix provided partial offsets. Abbott announced intentions in October 2026 to separate its Nutrition business by end of 2027 as an independent publicly traded company.
Tone: bullishRevenue
$44.3B
ABT 10-K · FY 2025
Employees
115,000
Revenue FY2024
$42B
Founded
1900
Profile
ABT 10-K Item 1 · Feb 20, 2026Abbott Laboratories is a diversified global healthcare company engaged in the discovery, development, manufacture, and sale of medical devices, diagnostic products, nutritional products, and branded generic pharmaceuticals. The company operates across four reportable segments and sells its products in more than 160 countries. Abbott is pursuing entry into the cancer diagnostics market through a pending acquisition of Exact Sciences Corporation.
Read filing description ↓ Collapse description ↑
Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment markets branded generic pharmaceuticals in emerging markets across broad therapeutic areas including gastroenterology, women's health, cardiovascular and metabolic conditions, pain and central nervous system disorders, respiratory drugs and vaccines, and biologics. The Diagnostic Products segment manufactures and markets core laboratory and transfusion medicine systems, molecular diagnostics PCR systems, point-of-care systems, rapid diagnostics lateral flow testing products, and informatics and automation solutions sold worldwide to blood banks, hospitals, commercial laboratories, clinics, and other care settings. The Nutritional Products segment offers pediatric and adult nutritional products, including infant formula, follow-on formula, and enteral nutrition products, marketed and sold worldwide to consumers, healthcare facilities, and institutional customers. The Medical Devices segment provides rhythm management, electrophysiology, heart failure, vascular, and structural heart devices, as well as continuous glucose monitoring systems, blood glucose monitoring systems, and neuromodulation devices for the management of chronic pain and movement disorders. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market.
Primary products
- Creon
- Duspatal
- Dicetel
- Heptral
- Transmetil
- Samyr
Business segments
End markets
Geographies
“Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Abbott's 2025 sales growth was primarily attributable to the performance of the Medical Devices and Established Pharmaceutical Products segments, partially offset by continued decline in COVID-19 testing-related sales in the Diagnostics segment.
The rest of ABT is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.